The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders.

Schally, Andrew V et al.·Reviews in endocrine & metabolic disorders·2025·not applicable (review)narrative review
RPEP-13450Narrative reviewnot applicable (review)2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
narrative review
Evidence
not applicable (review)
Sample
N=Not applicable (review article)
Participants
Preclinical models and early clinical data across oncology, regenerative medicine, and metabolic disorders

What This Study Found

GHRH agonists promote tissue regeneration, improve heart function, and help islet survival in diabetes models. GHRH antagonists show antitumor activity against lung, prostate, breast, and GI cancers with minimal toxicity in preclinical studies.

Key Numbers

GHRH antagonist series MIA and AVR demonstrated antitumor activity in preclinical models of lung, prostate, breast, and gastrointestinal cancers.

How They Did This

Narrative review of preclinical and early clinical literature on GHRH agonists and antagonists across oncology, regenerative medicine, and metabolic disorders.

Why This Research Matters

GHRH analogs may have therapeutic uses far beyond growth hormone regulation, spanning cancer, regenerative medicine, inflammation, and neurodegeneration.

What This Study Doesn't Tell Us

Review based mostly on preclinical data. Few human clinical trials. Long-term safety of GHRH analogs in these new indications is unknown.

Trust & Context

Original Title:
The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders.
Published In:
Reviews in endocrine & metabolic disorders, 26(3), 385-396 (2025)
Database ID:
RPEP-13450

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Cite This Study

RPEP-13450·https://rethinkpeptides.com/research/RPEP-13450

APA

Schally, Andrew V; Cai, Renzhi; Zhang, Xianyang; Sha, Wei; Wangpaichitr, Medhi. (2025). The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders.. Reviews in endocrine & metabolic disorders, 26(3), 385-396. https://doi.org/10.1007/s11154-024-09929-2

MLA

Schally, Andrew V, et al. "The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders.." Reviews in endocrine & metabolic disorders, 2025. https://doi.org/10.1007/s11154-024-09929-2

RethinkPeptides

RethinkPeptides Research Database. "The development of growth hormone-releasing hormone analogs:..." RPEP-13450. Retrieved from https://rethinkpeptides.com/research/schally-2025-the-development-of-growth

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.